6FK Stock Overview
Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 3.48 |
| 52 Week High | NOK 5.05 |
| 52 Week Low | NOK 2.99 |
| Beta | 0.56 |
| 11 Month Change | 1.16% |
| 3 Month Change | -21.27% |
| 1 Year Change | 1.46% |
| 33 Year Change | -49.12% |
| 5 Year Change | n/a |
| Change since IPO | -26.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6FK | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -2.8% | -2.5% | -1.3% |
| 1Y | 1.5% | -8.4% | 7.4% |
Return vs Industry: 6FK exceeded the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: 6FK underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 6FK volatility | |
|---|---|
| 6FK Average Weekly Movement | 6.1% |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6FK has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 6FK's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Njaal Kind | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| 6FK fundamental statistics | |
|---|---|
| Market cap | €54.55m |
| Earnings (TTM) | €192.46k |
| Revenue (TTM) | €13.36m |
283.4x
P/E Ratio4.1x
P/S RatioIs 6FK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6FK income statement (TTM) | |
|---|---|
| Revenue | NOK 154.12m |
| Cost of Revenue | NOK 67.86m |
| Gross Profit | NOK 86.26m |
| Other Expenses | NOK 84.04m |
| Earnings | NOK 2.22m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 55.97% |
| Net Profit Margin | 1.44% |
| Debt/Equity Ratio | 0% |
How did 6FK perform over the long term?
See historical performance and comparison